ESR1 and cancer: Up to 70% of patients with breast cancer are estrogen receptor positive (ER+) and can benefit from anti-estrogen therapy, Tamoxifen being most commonly prescribed for ER+ premenopausal breast cancer in order to prevent cancer relapse or metastases [1].